BASI, A Potent Small Molecular Inhibitor, Inhibits Glioblastoma Progression by Targeting microRNA-mediated β-Catenin Signaling.

CONCLUSIONS: Taken together, our findings offer preclinical validation of BASI as a promising new type of β-catenin inhibitor with a mechanism of inhibition that has broad potential for the improved treatment of glioblastoma. PMID: 24810017 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/24810017?dopt=Abstract

Source: CNS Neuroscience and Therapeutics - May 9, 2014 Category: Neuroscience Authors: Shi ZD, Qian XM, Zhang JX, Han L, Zhang KL, Chen LY, Zhou X, Zhang JN, Kang CS Tags: CNS Neurosci Ther Source Type: research